Syndax Pharmaceuticals
New York, New York, United States · Biopharma, Biotechnology, Healthcare
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Synda
Key facts
- Headquarters
- New York, New York, United States
- Employees
- 184
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (SNDX)
- Website
- syndax.com
- Company page
Recent activity at Syndax Pharmaceuticals
- : Syndax Pharmaceuticals Appoints Aaron A. Ondrey as Chief Financial Officer
- : SEC 8-K (8.01): On July 14, 2026, Syndax Pharmaceuticals, Inc. held an R&D event and issued a press release and corporate presentation that detailed its late-stage programs and new pipeline assets. This strategic initiative marks a significant chapter in the company's R&D strategy, aiming to enhance their development capabilities and potentially broaden their market reach. The activities and announcements made during this event are part of their ongoing efforts to innovate within their industry. The effective date of this event is July 14, 2026, corroborating the timeliness of the filing.
- : SEC 8-K (1.01): On June 10, 2026, Syndax Pharmaceuticals, Inc. entered into a material definitive agreement by issuing $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement. The notes were issued pursuant to an indenture with U.S. Bank Trust Company as trustee. The net proceeds from this private placement were approximately $243.0 million, intended for general corporate purposes, including working capital and research and development. This significant financial transaction reflects the company's strategic efforts to bolster its operational capabilities.
- : SEC 8-K (5.02): At Syndax Pharmaceuticals, Inc.'s 2026 Annual Meeting of Stockholders, held on June 10, 2026, the stockholders approved the 2026 Equity Incentive Plan, allowing the Board of Directors to grant various types of stock awards and reserving 7,200,000 shares. The previous 2015 Omnibus Incentive Plan will no longer grant awards following its expiration on March 6, 2026. Additionally, the stockholders approved the 2026 Employee Stock Purchase Plan, which aims to retain and incentivize employees. The 2026 ESPP includes components facilitating stock purchases for U.S. employees and foreign nationals. This approval reflects strategic efforts to enhance employee retention and align incentives with company performance.
- : SEC 8-K (1.01): On June 3, 2026, Syndax Pharmaceuticals, Inc. entered into privately negotiated subscription agreements with certain investors for the issuance of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031. The closing of this transaction is expected on June 10, 2026, pending customary conditions. The Notes will be senior unsecured obligations maturing on June 15, 2031, and will be convertible under specific conditions related to the Company's common stock performance. This agreement positions Syndax for increased capital and potential strategic growth in upcoming years.
- : SEC 8-K (7.01):
- : SEC 8-K (2.02): On January 12, 2026, Syndax Pharmaceuticals, Inc. reported preliminary financial results for the fiscal year ended December 31, 2025. The report highlighted that Revuforj® generated approximately $44 million and $125 million in U.S. net product revenue for the fourth quarter and the full year, respectively. Additionally, Niktimvo™ achieved $56 million and $152 million in U.S. net product revenue for the same periods. The company plans to report its share of net commercial profit in its full year 2025 results. This preliminary financial information is part of the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference, signifying strategic engagement with the investment community.
- : Syndax Pharmaceuticals Partners with World Orphan Drug Alliance to Expand Access to Revuforj® Globally.
- : SEC 8-K (8.01): On October 24, 2025, Syndax Pharmaceuticals, Inc. announced the FDA's approval of Revuforj® (revumenib) for treating relapsed or refractory acute myeloid leukemia (AML) in patients one year and older with a NPM1 mutation. This significant development offers a new treatment option for patients lacking satisfactory alternatives. The approval comes amidst various strategic plans to make the drug commercially available, demonstrating the company's commitment to addressing critical medical needs. The announcement was accompanied by a conference call to discuss its implications further.
- : Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Chief Medical Officer
Syndax Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2015 | Venture | $61.3M |
| Jun 2015 | Venture | $24.0M |
Leadership
- Aaron A. Ondrey, Chief Financial Officer
- Nicholas Botwood, Chief Medical Officer
- Steven Closter, Chief Commercial Officer
Verified email and direct lines for Syndax Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Syndax Pharmaceuticals files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Syndax Pharmaceuticals in the news
- Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program - Fierce Pharma (Oct 13, 2026)
- Why is Syndax Pharmaceuticals stock sliding today? - Investing.com (Oct 13, 2026)
- Syndax ends fibrosis program for Niktimvo after mid-stage disappointment - BioSpace (Oct 13, 2026)
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance (Oct 02, 2026)
- Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis - GlobeNewswire (Oct 12, 2026)
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX - PR Newswire (Nov 06, 2026)
- Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs - Fierce Pharma (Nov 05, 2024)
- Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 - GlobeNewswire (Jul 28, 2026)
Companies similar to Syndax Pharmaceuticals
- Parabilis Medicines · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Ligand Pharmaceuticals Incorporated · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Terns Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- OnKure Therapeutics · Biopharma, Biotechnology, Healthcare, Pharmaceutical
About Syndax Pharmaceuticals: questions and answers
What does Syndax Pharmaceuticals do?
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Synda
Where is Syndax Pharmaceuticals headquartered?
Syndax Pharmaceuticals is headquartered in New York, New York, United States.
How many employees does Syndax Pharmaceuticals have?
Syndax Pharmaceuticals has about 184 employees.
Has Syndax Pharmaceuticals raised funding?
Yes. Fundz has recorded 2 funding events for Syndax Pharmaceuticals. The most recent, $61.3M, was in Aug 2015.
What is the latest news on Syndax Pharmaceuticals?
On Nov 02, 2026, Syndax Pharmaceuticals Appoints Aaron A. Ondrey as Chief Financial Officer
Is Syndax Pharmaceuticals a public company?
Yes. Syndax Pharmaceuticals is publicly traded under the ticker SNDX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy